Everything below concerns pentapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
==== Adrenocortical carcinoma and tumors ==== Adrenocortical carcinoma occurs rarely; the average incidence rate is estimated to be 1–2 cases per million annually. The disease involves the formation of cancerous cells within the cortex of one or both of the adrenal glands. Although these tumors are identified in fewer than two percent of patients diagnosed with hyperandrogenism, the possibility must be considered within this population. In one study, more than half of tumor-affected patients had elevated levels of the androgens androstenedione, dehydroepiandrosterone sulfate, and testosterone. The elevation of androgens caused by adrenocortical carcinomas often causes patients to develop Cushing's syndrome, primary aldosteronism, and hyperandrogenism. The molecular basis of the disease has yet to be elucidated.
=== EC 1.4.3 With oxygen as acceptor === EC 1.4.3.1: D-aspartate oxidase EC 1.4.3.2: L-amino-acid oxidase EC 1.4.3.3: D-amino-acid oxidase EC 1.4.3.4: monoamine oxidase EC 1.4.3.5: pyridoxal 5′-phosphate synthase EC 1.4.3.6: replaced by two enzymes, EC 1.4.3.21 (primary-amine oxidase) and EC 1.4.3.22 (diamine oxidase) EC 1.4.3.7: D-glutamate oxidase EC 1.4.3.8: ethanolamine oxidase EC 1.4.3.9: Now included with EC 1.4.3.4 amine oxidase (flavin-containing) EC 1.4.3.10: putrescine oxidase EC 1.4.3.11: L-glutamate oxidase EC 1.4.3.12: cyclohexylamine oxidase EC 1.4.3.13: protein-lysine 6-oxidase EC 1.4.3.14: L-lysine oxidase EC 1.4.3.15: D-glutamate(D-aspartate) oxidase EC 1.4.3.16: L-aspartate oxidase EC 1.4.3.17: Now EC 1.3.3.10, tryptophan α,β-oxidase EC 1.4.3.18: Not approved as the enzyme was shown to be a dehydrogenase and not an oxidase (see EC 1.5.99.12, cytokinin dehydrogenase) EC 1.4.3.19: glycine oxidase EC 1.4.3.20: L-lysine 6-oxidase EC 1.4.3.21: primary-amine oxidase EC 1.4.3.22: diamine oxidase EC 1.4.3.23: 7-chloro-L-tryptophan oxidase EC 1.4.3.24: Now EC 1.4.2.3, pseudooxynicotine oxidase EC 1.4.3.25: L-arginine oxidase EC 1.4.3.26: pre-mycofactocin synthase
Eccles, Jessica A.; Cadar, Dorina; Quadt, Lisa; Hakim, Alan J.; Gall, Nicholas; Bowyer, Vicky; Cheetham, Nathan; Steves, Claire J.; Critchley, Hugo D.; Davies, Kevin A. (2024). "Is joint hypermobility linked to self-reported non-recovery from COVID-19? Case–control evidence from the British COVID Symptom Study Biobank". BMJ Public Health. 2 (1) e000478. doi:10.1136/bmjph-2023-000478. PMC 11812800. PMID 40018183.
On the other hand, all neuronal voltage-activated sodium channels inactivate within several milliseconds during strong depolarization, thus making following depolarization impossible until a substantial fraction of sodium channels have returned to their closed state. Although it limits the frequency of firing, the absolute refractory period ensures that the action potential moves in only one direction along an axon. The currents flowing in due to an action potential spread out in both directions along the axon. However, only the unfired part of the axon can respond with an action potential; the part that has just fired is unresponsive until the action potential is safely out of range and cannot restimulate that part. In the usual orthodromic conduction, the action potential propagates from the axon hillock towards the synaptic knobs (the axonal termini); propagation in the opposite direction—known as antidromic conduction—is very rare. However, if a laboratory axon is stimulated in its middle, both halves of the axon are "fresh", i.e., unfired; then two action potentials will be generated, one traveling towards the axon hillock and the other traveling towards the synaptic knobs.
== Removal of interfibrillary proteins == The interfibrillary proteins are denatured by the presence of alkali (particularly sodium sulfide), rendered soluble, facilitating their removal from the leather. Removal is done by the mechanical action of liming or reliming, but more prominently when the pelt is deswelled (during deliming). Failure to remove these proteins results in a hard, tinny leather (due to fibre glueing upon drying) that is brittle and inflexible.
Sources: en.wikipedia.org
Mass spectrometry (MS) is an analytical technique that is used to measure the mass-to-charge ratio of ions. The results are presented as a mass spectrum, a plot of intensity as a function of the mass-to-charge ratio. These spectra are used to determine the elemental or isotopic signature of a sample, the masses of particles and of molecules, and to elucidate the chemical identity or structure of molecules and other chemical compounds. Mass spectrometry is used in many different fields and is applied to pure samples as well as complex mixtures.
=== Surface modification improving cell adhesion === Surface modification can also affect properties that promote cell adhesion. One particular research in 2005 studied the mammalian cell adhesion on the modified surfaces of porous silicon. The research used rat PC12 cells and Human Lens Epithelial (HLE) cells cultured for four hours on the surface modified porous silicon. Cells were then stained with vital dye FDA and observed under fluorescence microscopy. The research concluded that "amino silanisation and coating the pSi surface with collagen enhanced cell attachment and spreading".
May lead to hypoglycemia or diabetes Increased risk of PCOS Increased synthesis of VLDL (hypertriglyceridemia) Hypertension (insulin increases sodium retention by the renal tubules) Coronary Artery Disease (increased insulin damages endothelial cells) Increased risk of cardiovascular disease Weight gain and lethargy (possibly connected to an underactive thyroid) Obesity and hyperinsulinemia have some links with some types of cancer
== AFL career == Fletcher was recruited by the Essendon Football Club in the 1992 National Draft. He played his first senior game against Carlton in his senior year of high school at Penleigh and Essendon Grammar School. Right from the get-go, Fletcher proved to be a highly impactful player. At 18 years old, he won a Longest Kick competition, a highly desirable trait that would serve him well for the next 22 years. He was a key member of the 1993 premiership team in his first AFL season, a team which is often referred to as the "Baby Bombers". Fletcher also played in the 2000 premiership team, a year in which he also won the Crichton Medal as Essendon's best and fairest and was selected in the All-Australian team.
RO-0282425 is a melanocortin MC4 receptor agonist which was under development for the treatment of erectile dysfunction but was never marketed. Its route of administration was unspecified. The drug was under development by Roche. It reached phase 2 clinical trials by 2005 but its development was subsequently discontinued. The chemical structure of RO-0282425, and whether it is a small molecule or a peptide, do not appear to have been disclosed.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.